BioSpace News Archive

Business

InspireMD Announces Third Quarter 2017 Results; CGuard Revenue Increases 90% Versus Same Period Last Year

Revenue for the third quarter ended September 30, 2017 was $718,000 compared to $469,000 during the same period in 2016.

November 7, 2017
·
18 min read
Business

Cutera Reports Third Quarter 2017 Financial Results

Revenue increased 26%, to a record $38.2 million, primarily due to 57% growth in North America Systems revenue.

November 7, 2017
·
28 min read
Genetown

Sarepta Therapeutics Announces Proposed Offering of $375 Million of Convertible Senior Notes Due 2024

The notes will be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

November 7, 2017
·
6 min read
Business

Retrophin Reports Third Quarter 2017 Financial Results

Net product sales for the third quarter of 2017 were $40.3 million, compared to $33.9 million for the same period in 2016.

November 7, 2017
·
25 min read
Business

Electromed Announces Fiscal 2018 First Quarter Financial Results

Gross profit rose 14.1% to $4.9 million from $4.3 million in Q1 FY 2017.

November 7, 2017
·
9 min read
Business

Invacare Reports Results for Third Quarter 2017

Reported net sales decreased 6.4% to $250.9 million compared to the third quarter last year.

November 7, 2017
·
24 min read
BIT Group to Display Molecular Instrumentation Solutions at AMP 2017

The AMP Annual Meeting is recognized as the premier gathering for molecular professionals as they seek to obtain critical, analytical patient care intelligence.

November 7, 2017
·
2 min read
Business

Dermira Reports Third Quarter 2017 Financial Results and Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients With Primary Axillary Hyperhidrosis

The FDA’s decision on New Drug Application expected by June 30, 2018.

November 7, 2017
·
15 min read
Deals

Spero Therapeutics Announces Closing of Initial Public Offering

The company has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of its common stock at the initial public offering price.

November 7, 2017
·
1 min read
Business

Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Collaboration and license revenue earned was $3.8 million for the third quarter of 2017, compared with $9.3 million for the third quarter of 2016.

November 7, 2017
·
8 min read